Building the investment case for asthma R&amp;D: the European Asthma Research and Innovation Partnership argument

Walker, Samantha; Akdis, C.; Dahlén, SE; Djukanović, Ratko; Edwards, Jessica; García‐Marcos, Luis; Johnston, SL; Kupczyk, Maciej; Martin, Thomas; Myles, David; Palkonen, Susanna; Papadopoulos, N; Powell, Pippa; Riley, John W.

doi:10.1111/cea.12779

Cited by 9 publications

(6 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This manuscript describes a state-of-the-art view of the mechanisms involved in asthma onset, asthma progression and asthma exacerbations and is an outcome of the European Asthma Research and Innovation Partnership (EARIP: www.earip.eu). Readers are also referred to companion EARIP reports including a report describing the vision and call to action resulting from the EARIP project, to explore pathways for optimising asthma research in Europe [1], a report on national and regional asthma programmes in Europe [2] and an editorial on building the case for more investment in asthma research in Europe [3].…”

Section: Executive Summarymentioning

confidence: 99%

Addressing unmet needs in understanding asthma mechanisms

et al. 2017

View full text Add to dashboard Cite

Asthma is a heterogeneous, complex disease with clinical phenotypes that incorporate persistent symptoms and acute exacerbations. It affects many millions of Europeans throughout their education and working lives and puts a heavy cost on European productivity. There is a wide spectrum of disease severity and control. Therapeutic advances have been slow despite greater understanding of basic mechanisms and the lack of satisfactory preventative and disease modifying management for asthma constitutes a significant unmet clinical need. Preventing, treating and ultimately curing asthma requires co-ordinated research and innovation across Europe. The European Asthma Research and Innovation Partnership (EARIP) is an FP7-funded programme which has taken a co-ordinated and integrated approach to analysing the future of asthma research and development. This report aims to identify the mechanistic areas in which investment is required to bring about significant improvements in asthma outcomes.

show abstract

Section: Executive Summarymentioning

confidence: 99%

Addressing unmet needs in understanding asthma mechanisms

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The study will therefore be aligning itself to the UK Severe Asthma Registry (previously the BTS Severe Asthma Registry) and the European Respiratory Society Clinical Research Collaboration on Severe Asthma. To this end, the Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) was formed following an Asthma UK-led pan-European project, which assesses the needs in severe asthma [40, 41]. Through a judicious process of harmonisation of protocols and variables collected, this will provide unprecedented data on large cohorts, thus improving understanding of disease mechanisms, sharing experiences and enabling improved asthma care across Europe through more targeted, stratified-medicine, therapeutic approaches.…”

Section: Discussionmentioning

confidence: 99%

Protocol for the Wessex AsThma CoHort of difficult asthma (WATCH): a pragmatic real-life longitudinal study of difficult asthma in the clinic

et al. 2019

View full text Add to dashboard Cite

Background Asthma is now widely recognised to be a heterogeneous disease. The last two decades have seen the identification of a number of biological targets and development of various novel therapies. Despite this, asthma still represents a significant health and economic burden worldwide. Why some individuals should continue to suffer remains unclear. Methods The Wessex Asthma Cohort of Difficult Asthma (WATCH) is an ongoing ‘real-life’, prospective study of patients in the University Hospital Southampton Foundation Trust (UHSFT) Difficult Asthma service. Research data capture is aligned with the extensive clinical characterisation required of a commissioned National Health Service (NHS) Specialist Centre for Severe Asthma. Data acquisition includes detailed clinical, health and disease-related questionnaires, anthropometry, allergy and lung function testing, radiological imaging (in a small subset) and collection of biological samples (blood, urine and sputum). Prospective data are captured in parallel to clinical follow up appointments, with data entered into a bespoke database. Discussion The pragmatic ongoing nature of the WATCH study allows comprehensive assessment of the real world clinical spectrum seen in a Specialist Asthma Centre and allows a longitudinal perspective of deeply phenotyped patients. It is anticipated that the WATCH cohort would act as a vehicle for potential collaborative asthma studies and will build upon our understanding of mechanisms underlying difficult asthma. Electronic supplementary material The online version of this article (10.1186/s12890-019-0862-2) contains supplementary material, which is available to authorized users.

show abstract

“…2. Необходимо интенсифицировать междисциплинарные и трансляционные исследования в сфере аллергии и астмы для изучения их этиологии, механизмов патогенеза, лечения и проведения анализа стоимости/ эффективности [1,20,21].…”

Section: французский национальный институт здоровья и медицинских иссunclassified

Prioritizing Research Challenges and Funding for Allergy and Asthma and the Need for Translational Research — The European Strategic Forum on Allergic Diseases

et al. 2020

View full text Add to dashboard Cite

The European Academy of Allergy and Clinical Immunology (EAACI) organized the first European Strategic Forum on Allergic Diseases and Asthma. The main aim was to bring together all relevant stakeholders and decision‐makers in the field of allergy, asthma and clinical Immunology around an open debate on contemporary challenges and potential solutions for the next decade. The Strategic Forum was an upscaling of the EAACI White Paper aiming to integrate the Academy’s output with the perspective offered by EAACI’s partners. This collaboration is fundamental for adapting and integrating allergy and asthma care into the context of real‐world problems. The Strategic Forum on Allergic Diseases brought together all partners who have the drive and the influence to make positive change: national and international societies, patients’ organizations, regulatory bodies and industry representatives. An open debate with a special focus on drug development and biomedical engineering, big data and information technology and allergic diseases and asthma in the context of environmental health concluded that connecting science with the transformation of care and a joint agreement between all partners on priorities and needs are essential to ensure a better management of allergic diseases and asthma in the advent of precision medicine together with global access to innovative and affordable diagnostics and therapeutics.

show abstract

Building the investment case for asthma R&D: the European Asthma Research and Innovation Partnership argument

Cited by 9 publications

References 2 publications

Addressing unmet needs in understanding asthma mechanisms

Addressing unmet needs in understanding asthma mechanisms

Protocol for the Wessex AsThma CoHort of difficult asthma (WATCH): a pragmatic real-life longitudinal study of difficult asthma in the clinic

Prioritizing Research Challenges and Funding for Allergy and Asthma and the Need for Translational Research — The European Strategic Forum on Allergic Diseases

Contact Info

Product

Resources

About